Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Dupilumab is cost-effective for adolescents and adults with uncontrolled severe asthma in South Korea. Our study provides evidence to support clinicians and policymakers in making informed decisions for severe asthma management.
Authors
- Hyemin Ku (ORCID: https://orcid.org/0009-0002-1699-5367)
- Chin Kook Rhee (ORCID: https://orcid.org/0000-0003-4533-7937)
- Sung-Hee Oh (ORCID: https://orcid.org/0000-0003-3002-9819)
- Eun Jin Bae
Institutions
- SK Group (United States) (US)
- Kyungpook National University (KR)
- Sanofi (South Korea) (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Health Economics Review
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1186/s13561-024-00532-4
- Citations
- 5
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Sanofi